Prophylactic Cranial Irradiation Following Surgical Resection of Early-Stage Small-Cell Lung Cancer: A Review of the Literature

Brooke C. Bloom1†, Alexander Augustyn2†, Boris Sepesi3, Sunil Patel4, Shalin J. Shah2, Ritsuko U. Komaki2, Steven E. Schild5† and Stephen G. Chun2*†

1 Trinity University, San Antonio, TX, United States, 2 Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 3 Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 4 Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 5 Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ, United States

With increasing use of low-dose screening CT scans, the diagnosis of early-stage small-cell lung cancer (SCLC) without evidence of mediastinal nodal or distant metastasis is likely to become more common, but the role of adjuvant therapies such as prophylactic cranial irradiation (PCI) are not well understood in this population. We performed a review of the literature pertaining to the impact of PCI in patients who underwent surgical resection of early-stage SCLC. Four studies were identified that were pertinent including three single-institution retrospective analyses and a National Cancer Database analysis. Based upon these studies, we estimate the rate of brain metastases to be 10–15% for Stage I and 15–25% for Stage II disease without PCI. However, the impact of PCI on the development of brain metastases and its ultimate impact on overall survival were not consistent across these studies. In summary, there is sparse evidence to guide recommendations for PCI following resection of early-stage SCLC. While it may be reasonable to offer PCI to maximize likelihood of cure, alternative strategies such as observation with close imaging follow-up can also be considered for the appropriate patient given the known neurocognitive side effects of PCI.

Keywords: small-cell lung cancer, early stage, surgical resection, prophylactic cranial irradiation, brain metastasis

BACKGROUND

Small-cell lung cancer (SCLC) is a common smoking-related malignancy that accounts for approximately 15% of all lung cancers (1, 2). For limited-stage SCLC (3), combined modality therapy with concurrent chemotherapy and early thoracic radiation (TRT), followed by prophylactic cranial irradiation (PCI) is considered to be the standard of care (4–7). Although not commonly performed, surgical resection for selected patients with early-stage tumors without evidence of mediastinal nodal metastases may be reasonable. However, the role of adjuvant therapies such as PCI for surgically resected early-stage SCLC has not been formally studied in a prospective clinical trial.

For limited-stage SCLC treated with curative-intent definitive chemoradiation, multiple studies have demonstrated that PCI reduces brain metastases and improves overall survival dating back to
the 1970s (2, 4, 8). The brain has long been established to be a sanctuary site for SCLC where there is poor chemotherapy penetration and roughly 50% of patients develop brain metastases (2, 9). However, in these studies, most patients had bulky and unresectable disease treated with chemoradiotherapy, and the applicability of this data to surgical resected early-stage SCLC is questionable. Moreover, the absolute survival benefit (5.4%) seen in the meta-analysis by Auperin et al. was small (4), suggesting that the benefit of PCI for surgically resected early-stage SCLC might be even smaller.

Historically, there have been few opportunities to study PCI for surgically resected SCLC. From a clinical standpoint, most limited-stage cases are not amenable for oncologic resection due to locally-advanced presentation. Furthermore, two historic trials did not demonstrate a clear role for surgery for SCLC (10, 11). For these reasons, there is little information available on surgical resection for SCLC and even less information available on the role of adjuvant therapy. For patients with early-stage SCLC (AJCC Stages I and II) who have undergone oncologic resection, the impact of adjuvant therapy such as PCI is debatable (12, 13). However, with increasing use of low-dose screening CT scans (LDCT), it is conceivable that patients with resected early-stage SCLC will become more common, particularly in regions that have high rates of tobacco use.

In this mini-review, we present the studies in the literature comparing outcomes of patients with and without PCI after surgical resection for early-stage (Stages I and II) SCLC. This included single-institution retrospective and a National Cancer Database (NCDB) analyses. The purpose of this review is to provide a concise resource to personalize recommendations for patients who have undergone surgical resection for early-stage SCLC.

METHODS

We performed a PubMed search using terms, “surgical resection,” “small-cell lung cancer,” “early-stage,” and “prophylactic cranial irradiation” to identify studies addressing the role of PCI for surgically resected SCLC. For the purpose of this mini-review, we excluded studies that did not include PCI. Using these criteria, three single institutional retrospective analyses (2, 14, 15), and a population-based analysis of the United States NCDB (16) were identified that compared outcomes of patients treated with and without PCI for surgically resected early-stage SCLC.

RESULTS

In reviewing the literature, three small single institution retrospective analyses were identified from the Tumor Hospital, Shan Dong Province, China (14), the Shanghai Chest Hospital, China (2), and the University of Heidelberg (15). In these studies, patients who underwent surgical resection for Stages I and III disease were compared with respect to whether they received PCI. A retrospective analysis of the United States NCDB that addressed PCI in this population with respect to overall survival was also identified (16). Rates of brain metastases reported in these studies are summarized in Table 1.

| Citation                          | Brain metastasis rate                  |
|----------------------------------|---------------------------------------|
| Xu et al. (2), Shanghai Chest Hospital | Stage I—13.6% (no PCI) vs. 10.5% (PCI) |
| Zhu et al. (14), Shandong Cancer Hospital | Stage I (no PCI)—9.4%                  |
| Bischof et al. (15), University of Heidelberg | Stage I (no PCI)—18.2%                |
|                                  | Stages I and II combined—22%           |

PCI, prophylactic cranial irradiation.

In the largest study by Xu et al. (2) from the Shanghai Chest Hospital, 349 patients were analyzed, of whom 115 received PCI and 234 did not receive PCI. Approximately half (N = 189) of the patients had Stages I and II disease for whom the association of PCI on oncologic outcomes is summarized in Table 1. For Stage I SCLC, patients who received PCI had no survival advantage (HR 1.61, 95% CI 0.68–3.83) or associated reduction in development of brain metastases (13.6 vs. 10.5%). For Stage II SCLC, PCI was associated with an overall survival benefit on multivariable analysis (HR 0.54, p = 0.047), as well as a statistical trend toward reduction in brain metastases (22.4 vs. 12.8%, p = 0.094).

In another single institution analysis from the Tumor Hospital, Shan Dong, China, 193 patients were analyzed with respect to delivery of PCI after surgical resection for Stages I–III SCLC (14). While PCI was associated with a survival and brain metastasis free survival benefit in all patients, subgroup analysis of Stage I patients showed no survival benefit associated with PCI. PCI was associated with a twofold reduction in brain metastases with 9% of developing them in the PCI group and 22% in the non-PCI group. The non-PCI brain metastasis rates were listed as 9.4% for Stage I and 18.2% for Stage II. Further subgroup analysis comparing brain metastases rates by stage groups was not reported.

The smallest study evaluating the impact of PCI on rates of brain metastases from the University of Heidelberg reported 39 patients who underwent resection for Stages I and II SCLC from 1995 to 2006 (15). This study contains the additional confounding factor in that it sought to evaluate both the role of adjuvant thoracic radiation therapy (TRT) as well as the role of PCI on a very small number of patients. PCI was administered to a total dose of 28–30 Gy in standard fractions of 2 Gy daily. In this study, 44% of patients received no form of radiation, while 15% received PCI alone, 3% received TRT alone, and 38% received both PCI and TRT. Rates brain metastases were grouped for all Stages I and II patients with a 22% brain metastasis rate for patients without PCI and no brain failures reported in the PCI group. The authors reported that PCI had a significant (p = 0.01) survival benefit although the magnitude of this benefit is not reported.

From the United States, an NCDB analysis was performed on patients treated with surgical resection for T1-T2N0 SCLC from 2003 to 2011 (16). In this study, 99 patients (52.1%) of patients received radiation therapy to the brain, which was interpreted as PCI delivery. On multivariable analysis, radiation was not associated with a significant survival benefit when used either alone
or in conjunction with chemotherapy. Information on rates of brain metastases was not reported because such information is not captured in the NCDB.

**DISCUSSION**

Currently, the best available information on PCI for early-stage SCLC is based upon underpowered retrospective analyses that do not set a clear precedent for standard of care. These retrospective studies help us estimate the brain metastasis rate for early-stage SCLC to be roughly 10–15% for Stage I disease and for 15–25% for Stage II disease. PCI is known to cause neurocognitive side effects (17), and the overall survival benefit is likely to be less than 5% based upon extrapolation from unresectable SCLC (1). Without a clear standard of care regarding PCI in these patients, we advocate multidisciplinary evaluation and patient-tailored recommendations. While offering PCI may be reasonable to maximize likelihood of cure, close interval follow-up using serial brain MRIs may also be a reasonable strategy in the compliant patient.

Exploration of PCI for resected early-stage SCLC may represent an opportunity for investigation with the implementation of LDCT. Multiple prospective trials lead the conclusion from the United States Preventative Task Force that LDCT reduce lung cancer mortality (18). With increasing use of screening, thoracic surgeons using video-assisted thoracoscopic surgery for diagnostic wedge resection may also increase diagnoses of early-stage SCLC. Analyses of the Surveillance, Epidemiology, and End Results Program database have also supported a role for surgical resection for this population (19, 20). As such, especially in geographic regions where tobacco use remains prevalent, early-stage resected SCLC may become more common with increased screening and early detection. While a formal randomized trial for this situation may not be feasible, it may be possible to develop a prospective registry to better understand oncologic outcomes in these patients. Data from such a registry might also provide useful information in conjunction with molecular profiling to shed light on the need for adjuvant treatments such as PCI, immune therapy, or cytotoxic chemotherapy.

Although PCI has been established to cause neurocognitive side effects in a substantial number of patients, emerging strategies may mitigate the risk of this toxicity. The N-methyl-D-aspartate inhibitor memantine has previously shown to improve neurocognitive side effects from whole-brain radiation therapy for patients with overt metastases (21). Intensity-modulated radiation therapy has also been employed with hippocampal avoidance specifically for the purpose of improving neurocognition (22, 23). These strategies have been combined in NRG Oncology CC-001 with the intent of improving quality of life and cognition for patients receiving prophylactic whole-brain radiation. Results of NRG Oncology CC-001 will be helpful in determining whether PCI with hippocampal avoidance is a reasonable strategy to prevent brain failures while minimizing neurocognitive consequences.

In summary, there is little information currently available on PCI for resected early-stage SCLC. With increased screening, these patients may represent a new frontier for investigation. It may be reasonable to offer PCI for the purpose of minimizing intracranial recurrence rate while counseling patients that the reduction in brain metastases and improvement in survival is likely to be small. While the side effects of whole-brain PCI may be unpalatable to some patients, strategies such as memantine and hippocampal avoidance have potential to mitigate the toxicities of PCI and should be explored enthusiastically.

**AUTHOR CONTRIBUTIONS**

BB and AA: contributed to data collection and writing of manuscript. SJS, BS, and RK: contributed to data interpretation and writing of manuscript. SES and SC: contributed to data interpretation, data collection, and writing of manuscript.

**REFERENCES**

1. Govindan R, Page N, Morgenstern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. *J Clin Oncol* (2006) 24(28):4539–44. doi:10.1200/JCO.2005.04.4859

2. Xu J, Yang H, Fu X, Jin B, Lou Y, Zhang Y, et al. Prophylactic cranial irradiation for patients with surgically resected small cell lung cancer. *J Thorac Oncol* (2017) 12(2):347–53. doi:10.1016/j.jtho.2016.09.133

3. Micke P, Faldum A, Meta T, Beeh KM, Bittinger F, Hengstler JG, et al. Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer – what limits limited disease? *Lung Cancer* (2002) 37(3):271–6. doi:10.1016/S0169-5002(02)00072-7

4. Auperin A, Arriaga R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. *N Engl J Med* (1999) 341(7):746–84. doi:10.1056/NEJM199908123410703

5. Pignon JP, Arriaga R. Role of thoracic radiotherapy in limited-stage small-cell lung cancer: quantitative review based on the literature versus meta-analysis based on individual data. *J Clin Oncol* (1992) 10(11):1819–20. doi:10.1200/JCO.1992.10.11.1819

6. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* (2013) 143(5 Suppl):e400S–e19S. doi:10.1378/chest.12-2363

7. Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. *Cancer* (2014) 120(6):790–8. doi:10.1002/cncr.28505

8. Aroney RS, Aisner J, Wesley MN, Whittacre MY, Van Echo DA, Slawson RG, et al. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. *Cancer Treat Rep* (1983) 67(7–8):675–82.

9. Arriaga R, Le Chevalier T, Riviere A, Charmy P, Monnet I, Bardet E, et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. *Ann Oncol* (2002) 13(5):748–54. doi:10.1093/annonc/md212

10. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to chemotherapy. *Chest* (1994) 106(6 Suppl):320S–3S. doi:10.1093/chest/106.6.320S

11. Fox W, Scadding JG. Medical research council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. *Lancet* (1973) 2(7820):63–5. doi:10.1016/S0140-6736(73)93260-1

12. Fruh M, De Ruyscher D, Popat S, Crino L, Peters S, Felp U, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* (2013) 24(6 Suppl 6):v199–105. doi:10.1093/annonc/mdt178
13. Le Pechoux C. Prophylactic cranial irradiation or no prophylactic cranial irradiation after adjuvant chemotherapy in resected small cell lung cancer? J Thorac Oncol (2017) 12(2):173–5. doi:10.1016/j.jtho.2016.12.002

14. Zhu H, Guo H, Shi E, Zhu K, Luo J, Liu X, et al. Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer, but not for stage I disease. Lung Cancer (2014) 86(3):334–8. doi:10.1016/j.lungcan.2014.09.019

15. Bischof M, Debus J, Herfarth K, Muley T, Kappes J, Storz K, et al. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy. Strahlenther Onkol (2007) 183(12):679–84. doi:10.1007/s00066-007-1740-z

16. Yang CF, Chan DY, Speicher PJ, Gulack BC, Wang X, Hartwig MG, et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol (2016) 34(10):1057–64. doi:10.1200/JCO.2015.63.8171

17. Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys (2011) 81(1):77–84. doi:10.1016/j.ijrobp.2010.05.013

18. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2014) 160(5):330–8. doi:10.7326/M13-2771

19. Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer A-M, DeCamp MM. Lobectomy leads to optimal survival in early-stage small cell lung cancer: a retrospective analysis. J Thorac Cardiovase Surg (2011) 142(3):538–46. doi:10.1016/j.jtcvs.2010.11.062

20. Schreiber D, Rineer J, Weedon J, Vongtama D, Wortham A, Kim A, et al. Survival outcomes with the use of surgery in limited-stage small-cell lung cancer: should its role be re-evaluated? Cancer (2010) 116(5):1350–7. doi:10.1002/cncr.24853

21. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol (2013) 15(10):1429–37. doi:10.1093/neuonc/not114

22. Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, et al. Hippocampal-sparing whole-brain radiotherapy: a “how-to” technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy, Int J Radiat Oncol Biol Phys (2010) 78(4):1244–52. doi:10.1016/j.ijrobp.2009.01.039

23. Lin SY, Yang CC, Wu YM, Tseng CK, Wei KC, Chu YC, et al. Evaluating the impact of hippocampal sparing during whole brain radiotherapy on neurocognitive functions: a preliminary report of a prospective phase II study. Biomed J (2015) 38(3):439–49. doi:10.4103/2319-4170.157440

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Bloom, Augustyn, Sepesi, Patel, Shah, Komaki, Schild and Chun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.